Thus, while nucleic acid therapeutics show promise in targeting STAT3 in cancer, clinical inhibition of STAT3 in GBM is still dependent on the development of effective pharmacological agents which can cross the BBB. This evidence concerns the gene STAT3 and glioblastoma.